RCM
VRTX icon

Raleigh Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Raleigh Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.1K Sell
119
-18
-13% -$7.98K 0.02% 270
2026
Q1 		$61.2K Buy
137
+17
+14% +$7.93K 0.02% 266
2025
Q4 		$54.4K Sell
120
-6
-5% -$2.59K 0.02% 273
2025
Q3 		$49.3K Sell
126
-5
-4% -$2.09K 0.02% 269
2025
Q2 		$58.3K Sell
131
-342
-72% -$158K 0.02% 261
2025
Q1 		$229K Buy
473
+237
+100% +$110K 0.1% 184
2024
Q4 		$95K Sell
236
-13
-5% -$6.03K 0.04% 254
2024
Q3 		$116K Buy
249
+2
+0.8% +$961 0.04% 251
2024
Q2 		$116K Buy
247
+35
+17% +$15.2K 0.05% 235
2024
Q1 		$88.6K Buy
212
+162
+324% +$68.5K 0.04% 246
2023
Q4 		$20.4K Buy
50
+30
+150% +$11.1K 0.01% 436
2023
Q3 		$7.01K Buy
20
+1
+5% +$350 ﹤0.01% 620
2023
Q2 		$6.69K Hold
19
– – ﹤0.01% 573
2023
Q1 		$5.99K Buy
+19
New +$5.7K ﹤0.01% 586
2022
Q1 		– Sell
-4
Closed -$1K – 689
2021
Q4 		$1K Buy
+4
New +$778 ﹤0.01% 299

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Raleigh Capital Management's VRTX Position: Q2 2026 in Review

Raleigh Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, selling an estimated $7.98K and leaving 119 shares worth $59.1K. The position accounts for 0.02% of the portfolio, ranked #270.

Raleigh Capital Management first reported a position in VRTX in Q4 2021 and has held it in 15 quarters since. The position peaked at $229K in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Raleigh Capital Management held 119 shares of Vertex Pharmaceuticals worth $59.1K as of Q2 2026.
  • Raleigh Capital Management sold 18 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.98K.
  • Vertex Pharmaceuticals made up 0.02% of Raleigh Capital Management's portfolio in Q2 2026, its #270 holding.
  • Raleigh Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Raleigh Capital Management's Vertex Pharmaceuticals position peaked at $229K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.